Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 11.34 AUD 3% Market Closed
Market Cap: 1.4B AUD

Neuren Pharmaceuticals Ltd
Investor Relations

Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors.

The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.

Show more
Loading

Earnings Calls

2024 Q1
May 8, 2024
Show Transcript
Previous
Next
Company Achieves Strong Q1 Despite Normalization
2024 Q1
May 8, 2024

In Q1 2024, the company reported an EBITDA of EUR 1.1 billion, 26% lower than the previous year's exceptional results. Net ordinary income fell by 51% to EUR 0.3 billion. FFO improved to EUR 0.2 billion despite a EUR 0.5 billion arbitration payment, and net debt stood just above EUR 11 billion. Gas sales dropped by 27%, with margins normalizing from EUR 6 to EUR 2 per megawatt hour. Hydro production increased by 42%. The company maintains its 2024 guidance, expecting EBITDA of EUR 1.3-1.4 billion per quarter for the rest of the year.

Show Full Analysis

Management

Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
CEO, MD & Executive Director
No Bio Available
Ms. Lauren Frazer C.A.
CFO & Company Secretary
No Bio Available
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
No Bio Available
Mr. Gerry Zhao
Vice President of Corporate Development
No Bio Available
Dr. Liza A. Squires M.D.
Chief Medical Officer
No Bio Available

Contacts

Address
VICTORIA
Melbourne
SE 201 697 Burke Rd, Camberwell
Contacts
+61390920480.0
www.neurenpharma.com